Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) with or without rituximab plus recombinant Erwinia asparaginase (JZP458) works in treating patients with newly diagnosed Philadelphia chromosome (Ph) negative B-acute lymphoblastic leukemia (ALL) or T-ALL. Chemotherapy drugs, such as etoposide, vincristine, cyclophosphamide and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. JZP458 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving DA-EPOCH with or without rituximab plus JZP458 may kill more cancer cells in patients with newly diagnosed Ph negative B-ALL or T-ALL.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby dorosłe (18 lat i starsze) z nowo zdiagnozowaną ostrą białaczką limfoblastyczną (ALL) typu B lub T bez cechy "Philadelphia".
- •Pacjenci, u których lekarz uznał, że standardowe leczenie dla dzieci nie jest odpowiednie (np. z powodu wieku, trudności w podaniu lub obaw o skutki uboczne).
- •Wykrywalna obecność ALL w szpiku lub krwi.
- •Ogólny stan zdrowia umożliwiający leczenie (ECOG 0-2, lub 3 jeśli spowodowane przez ALL).
- •Określone parametry pracy wątroby i nerek pozwalające na bezpieczne leczenie.
- •Zdolność do świadomej zgody na udział w badaniu i przestrzegania jego zasad.
- •Przewidywany czas przeżycia co najmniej 3 miesiące.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Fred Hutch/University of Washington Cancer Consortium
Seattle, United States
Trial contact
Kim Quach
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.